All News
Interesting poster #POS0939 from @SteZhao #EULAR2026
Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals
11,611 HLA-B27+ UK biobank
Recall bias? Yes but self-reported exposure validated with primary care data
@RheumNow https://t.co/VmxI3BW6FE
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Can AI read 20yrs of #RA X-rays as well as experts? RADAR algorithm scored 7,560 joints from the ESPOIR cohort: accuracy 0.94, sensitivity 0.92, specificity 0.95. AI-assisted radiographic scoring at scale and at the point of care may be here. @RheumNow #EULAR2026 OP0344
Jiha Lee JihaRheum ( View Tweet)
Have you ever thought of diclofenac as an environmental pollutant?
Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026
@rheumnow https://t.co/RJWB6DmiZh
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0338 More evidence for treatment-to-target in #SLE. Longitudinal renal function analysis of Asia Pacific cohort: achieving LLDAS at least 50% of the time (LLDAS50) is assoc. with reduced eGFR decline independent of age, baseline eGFR, & renal involvement @RheumNow https://t.co/KduU1qtkhF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
sheila RHEUMarampa ( View Tweet)
Understanding how Bispecific T cell engagers work: remarkable mode of action!
Let’s hope it works as well as in oncology!
#teclistamab in #SSc
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/waSCXKA79Y
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#CAR_T cell therapy in #SSc
Promising results from the Breakfree-1 study
(Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients
More data is needed
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Looking forward to CAR T cell therapy trials in #SSc
Phase 2 and 3 studies presented at
#HOT session by Pr Oliver Distler
#CAR_T
#EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy
Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/I7HQtfwuW0
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up.
Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
How many patients from real life fulfill the inclusion criteria of clinical trials?
Not so many ⬇️
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/U6vlzOYS4X
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#OP0349 Higher pericoronary fat attenuation (PCATa) in RA vs controls, with PCATa assoc with coronary plaque burden only in RA. Suggests coronary inflammation may precede overt plaque changes; supports PCATa as potential CV inflammation biomarker in RA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0348 CT-based analysis in RA showed increased subcutaneous and intermuscular fat plus reduced muscle quality versus non-RA comparators, despite similar BMI-adjusted muscle area and visceral fat. Highlights “hidden” adverse body composition changes in RA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Optical spectral transmission (OST) a non-invasive light-based scan of hand joints monitored inflammatory arthritis activity over time in 60 patients, 1,312 joints.
OST correlated with DAS28-CRP (r=0.500, p<0.001), swollen joint count (r=0.535, p<0.001), and AUC 0.781 for https://t.co/AHrybe1Rrn
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#OP0347 In CCP-positive at-risk individuals with MSK symptoms, MRI-detected hand tenosynovitis independently predicted progression to IA (HR 1.21), alongside US positivity (HR 2.77). MRI added little predictive value in patients with negative US findings. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0346 In clinically suspect arthralgia, US missed ~3/4 cases of tenosynovitis detected by modified Dixon MRI. Compared to mDixon MRI, US sensitivity was 23%; specificity remained 100%. Potential for fast non-contrast MRI in early RA risk stratification. #EULAR2026 @RheumNow https://t.co/h3FhLEC2je
Mrinalini Dey DrMiniDey ( View Tweet)
